Trial Profile
Continuation Protocol For G3139 (Bcl-2 Antisense Oligonucleotide) And Dacarbazine In Patients With Malignant Melanoma Who Responded To This Combination In Protocol GM301.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Dacarbazine (Primary) ; Oblimersen (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 10 Oct 2005 New trial record.